Tekmira is a leader in the development of therapeutic agents based upon Nobel Prize winning breakthroughs in the field of gene silencing, known as RNA interference (RNAi). Tekmira's lead RNAi product candidates target cancer, Ebola infection, high cholesterol and other indications. http://www.tekmirapharm.com/Home.asp
Das Arbutus bisher aus der allgemeinen Situation der Corona-Pandemie bisher keinen Nutzen ziehen konnte halte ich für ein negatives Zeichen. Viele Pharma Firmen konnten davon profitieren. Und die Entwicklung eines Medikaments zur Heilung von Hepatitis-B- scheint wohl auch nicht der große Gewinnbringer zu sein.
Der erwähnt z.B. die nächste Verhandlung gegen Moderna für den 07.10.2021 --
Dann gibts noch die News von vorgestern zu 2 kommenden Investorenveranstaltungen. Das treibt aber normalerweise keine Kurse.. https://investor.arbutusbio.com/news-releases/...vestor-conferences-9 "Sep 07, 2021 WARMINSTER, Pa., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that the Company will participate in the following upcoming virtual investor conferences:
H.C. Wainwright 23rd Annual Global Investment Conference (September 13-15, 2021)
Fireside Chat: available starting at 7:00 am ET on Monday, September 13, 2021 Presenters: William Collier, President and Chief Executive Officer; Dr. Michael Sofia, Chief Scientific Officer; Dr. Gaston Picchio, Chief Development Officer; and David Hastings, Chief Financial Officer Webcast Link Cantor Global Healthcare Conference (September 27-30, 2021)
Formal Presentation: Thursday, September 30, 2021 at 8:40 am ET Presenter: William Collier, President and Chief Executive Officer Webcast Link The webcast links can also be accessed through the Investors section of Arbutus' website at www.arbutusbio.com. An archived replay of the webcast will be available on the Company?s website after the conference."
-- Charttechnisch ist ein Anstieg durchaus erklärbar, aber eigentlich nicht in dieser Stärke..
"Shares of Arburtus Biopharma (NASDAQ:ABUS) closed up 15% amid speculation it has won a patent fight against Moderna (NASDAQ:MRNA). Arbutus may receive a new patent and as a result, may be eligible to royalties from Moderna from sales of its COVID-19 vaccine. The U.S. Patent and Trademark Office website shows that Arbutus was granted a notice of allowance on Sept. 2 for a patent covering novel lipid formulations for nucleic acid delivery. In the past, Moderna has unsuccessfully challenged similar patents. Moderna is appealing the validity of those patents with a hearing before a federal appellate court on Oct. 7 An article published in Forbes last month highlighted that scientific papers and regulatory documents indicate that both Moderna's vaccine and Pfizer (NYSE:PFE)/BioNTech's (NASDAQ:BNTX) use a delivery system that is quite similar to what Ian McLachlan, who worked at Tekmira, which later changed its name to Arbutus, created." https://seekingalpha.com/news/...parent-patent-fight-win-with-moderna
Außergerichtliche Einigung mit Moderna gegen Geldzahlung Moderna kauft Arbutus. Problem ist Roivant das ebenfalls an Genevant beteiligt ist Roivant stockt Anteile an Arbutus auf und eskaliert den Konflikt mit Moderna Keine Einigung bis zum Gerichtstermin im Oktober. Nicht gut für Moderna Short Squeeze? Ich bin sehr gespannt aber auch äußerst zuversichtlich
Fireside Chat: Tuesday, October 5, 2021 at 4:30 pm ET Presenters: William Collier, President and Chief Executive Officer; Dr. Michael Sofia, Chief Scientific Officer; Dr. Gaston Picchio, Chief Development Officer; and David Hastings, Chief Financial Officer H.C. Wainwright Hepatitis B Virus (HBV) Virtual Conference (October 13, 2021)
Fireside Chat: Wednesday, October 13, 2021 at 1:00 pm ET Presenters: William Collier, Dr. Michael Sofia, Dr. Gaston Picchio, and David Hastings The live webcast links for the fireside chats can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com. An archived replay of the webcast will be available on the Company?s website after the conference."
First patient dosed in Phase 2a clinical trial combining AB-729, Peg-IFN?-2a and nucleos(t)ide analog (?NA?) therapy
On-track to initiate several proof-of-concept Phase 2a clinical trials with AB-729 as a cornerstone agent in combination with other approved or investigational compounds
Commenced IND enabling studies for Arbutus? oral PD-L1 program
Cash runway guidance extended into the second quarter of 2023
Conference call and webcast scheduled today at 8:45 AM ET
WARMINSTER, Pa., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of wholly-owned assets with different mechanisms of action to provide a cure for people with chronic hepatitis B virus (HBV) infection and to treat coronaviruses (including COVID-19), today reports its third quarter 2021 financial results and provides a corporate update.
William Collier, President and Chief Executive Officer of Arbutus, stated, ?We are impressed with the continued development of our proprietary HBV assets that align with our novel three-pronged approach to develop an HBV functional cure by suppressing HBV DNA, reducing HBV surface antigen and boosting the host immune system. We have clinical trials underway assessing our RNAi therapeutic and capsid inhibitor in both healthy subjects and patients with chronic HBV infection and are poised for multiple data readouts in the fourth quarter of this year. We expect these data will further inform the design of future combination clinical trials with AB-729 as a cornerstone agent in HBV treatment.?
Mr. Collier continued, ?Importantly, we have now moved forward with IND enabling studies for our internally-discovered oral PD-L1 program intended to address the third arm of our three-prong approach, reawakening the host immune response. In addition, we are continuing to conduct lead optimization activities for our oral RNA destabilizer in HBV and to progress our efforts to identify lead candidates for our pan-coronavirus program. We intend to provide additional updates on these programs early next year.? ...